NCT07177339View on ClinicalTrials.gov

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

1,196

Participants

Timeline

Start Date

October 20, 2025

Primary Completion Date

October 19, 2029

Study Completion Date

December 14, 2029

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Depemokimab

Depemokimab will be administered.

DRUG

Placebo

Matching placebo will be administered.

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY